AR029887A1 - Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen - Google Patents
Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienenInfo
- Publication number
- AR029887A1 AR029887A1 ARP000105125A ARP000105125A AR029887A1 AR 029887 A1 AR029887 A1 AR 029887A1 AR P000105125 A ARP000105125 A AR P000105125A AR P000105125 A ARP000105125 A AR P000105125A AR 029887 A1 AR029887 A1 AR 029887A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally
- mono
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000028867 ischemia Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229920006395 saturated elastomer Polymers 0.000 abstract 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 239000001301 oxygen Substances 0.000 abstract 7
- 239000011593 sulfur Chemical group 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000002619 bicyclic group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- -1 oxy, methylene Chemical group 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un compuesto caracterizado por que tiene la formula 1 un profármaco del mismo o una sal farmacéuticamente aceptable de dicho compuesto o de dicho profármaco, en la que X es oxi, metileno, o tio; Y es CH o N; Z es H, alquilo (C1-4), alquil (C1-4)-oxi, trifluorometilo o halo; R1 es hidroximetilo, alcoxi (C1-3)-metilo, cicolalcoxi (C3-5)-metilo, carboxi, alcoxi (C1-3)-carbonilo, cicloalcoxi (C3-5)-carbonilo, 1,1-aminoiminometilo, 1,1-(mono-N- o di-N, N-alquil (C1-4)-amino)iminometilo, 1,1-(mono-N- o di-N, N-cicloalquil (C3-5) -amino)iminometilo, carbamoílo, mono-N-, o di-N, N-alquil (C1-4)-aminocarbonilo, mono-N o di-N, N-cicloalquil (C3-5)-aminocarbonilo o N-alquil (C1-4) - N-cicloalquil (C3-5) -aminocarbonilo; R2 es H, alquilo (C1-3), o cicloalquilo (C3-5); R3 es halo, trifluorometilo, ciano, alquilo (C1-3), alquil (C1-3)-oxi, etenilo o etinilo; D es oxi, tio, NH, alquil (C1-6)-oxi, alquil (C1-6)-tio o alquil (C1-6)-amino; G es un anillo de cinco a ocho miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a tres heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrogeno, o un anillo bicíclico que consta de dos anillos de tres a seis miembros condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente, entre nitrogeno, azufre y oxígeno; estando dicho G opcionalmente mono-, di- o tri- sustituido independientemente con halo, alquilo (C1-3), trifluorometilo, trifluorometoxi, nitro, ciano, cicloalquilo (C3-5), hidroxi o alcoxi (C1-3) o G es ciano, alcoxi (C1-4) carbonilo, cicloalcoxi (C3-5)-carbonilo, C (O) NR4R5, C (S) NR4R5, C (NH) NR4R5, C (N-alquil (C1-3)) NR4R5 o C (N-cicloalquil (C3-10)) NR4R5; R4 es un enlace, H, alquilo (C1-10), hidroxi, alcoxi (C1-10), cicloalcoxi (C3-10) o un anillo de cinco a ocho miembros parcialmente saturado o totalmente insaturado, opcionalmente unido a través de alquilo (C1-3), que tiene opcionalmente de uno a tres heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrogeno, o un anillo bicíclico o un anillo bicíclico con un puente (C1-3) opcional (por ejemplo, adamantano) opcionalmente unido a través de alquilo (C1-3), teniendo dicho anillo bicíclico o anillo bicíclico enlazado opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre nitrogeno, azufre y oxígeno, y estando dichos alquilo (C1-10), alcoxi (C1-10), cicloalcoxi (C3-10) o anillos de R4 opcionalmente mono., di- o tri- sustituidos independientemente con halo, alquilo (C1-3), trifluorometilo, nitro, ciano, cicloalquilo (C3-5), hidroxi o alcoxi (C1-3); R5 es un enlace, H, alquilo (C1-10) o cicloalquilo (C1-10); o R4 y R5, tomados junto con el nitrogeno al que están unidos, forman un anillo de cuatro a nueve miembros totalmente saturado o parcialmente insaturado, estando dicho anillo opcionalmente enlazado, que tiene opcionalmente de uno a tres heteroátomos adicionales seleccionados independientemente entre oxígeno, azufre y nitrogeno, estando dicho anillo opcionalmente mono- o di- sustituido independientemente con oxo, hidroxi, alcoxi (C1-6), alquilo (C1-8), amino, mono-N- o di-N,N-alquil (C1-4)-aminocarbonilo, mono-N- o di-N, N-cicloalquil (C3-5)-aminocarbonilo, N-alquil (C1-4)-N-cicloalquil (C3-5)-aminocarbonilo, mono o di-N, N-alquil (C1-4)-amino, mono-N- o di-N, N- cicloalquil (C3-5)-amino, N-alquil (C1-4)-N-cicloalquil (C3-5)-amino, formilamino, alquil (C1-4)-carbonilamino, cicloalquil (C3-5)-carbonilamino, alcoxi (C1-4)-carbonilamino, N-alcoxi (C1-4)-carbonil-N-alquil(C1-4)-amino, sulfamoílo (C1-4), alquil (C1-4)-sulfonilamino, cicloalquil (C3-5)-sulfonilamino o un anillo de cinco a ocho miembros parcialmente saturado, totalmente saturado o totalmente insaturado, opcionalmente unido a través de alquilo (C1-3), que tiene opcionalmente de uno a tres heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrogeno, o un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, opcionalmente unidos a través de alquilo (C1-3), que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre nitrogeno, azufre y oxígeno, opcionalmente mono- o di- sustituidos con halo, trifluorometilo, trifluorometoxi, alquilo (C1-3) o alcoxi (C1-3). Los agonistas de A3 son utiles para la reduccion de lesiones de tejidos producidas por isquemia o hipoxia de los tejidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682899P | 1999-09-30 | 1999-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029887A1 true AR029887A1 (es) | 2003-07-23 |
Family
ID=22561263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105125A AR029887A1 (es) | 1999-09-30 | 2000-09-28 | Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1216257B1 (es) |
| JP (1) | JP2003510331A (es) |
| KR (1) | KR100481605B1 (es) |
| CN (1) | CN1374967A (es) |
| AP (1) | AP2002002458A0 (es) |
| AR (1) | AR029887A1 (es) |
| AT (1) | ATE312117T1 (es) |
| AU (1) | AU778185B2 (es) |
| BG (1) | BG106636A (es) |
| BR (1) | BR0014384A (es) |
| CA (1) | CA2386079A1 (es) |
| CO (1) | CO5180581A1 (es) |
| CR (1) | CR6592A (es) |
| CZ (1) | CZ20021020A3 (es) |
| DE (1) | DE60024649D1 (es) |
| EA (1) | EA005422B1 (es) |
| EC (1) | ECSP003682A (es) |
| EE (1) | EE200200172A (es) |
| GE (1) | GEP20043241B (es) |
| GT (1) | GT200000161A (es) |
| HK (1) | HK1049011A1 (es) |
| HR (1) | HRP20020253A2 (es) |
| HU (1) | HUP0202807A3 (es) |
| IL (1) | IL148222A0 (es) |
| IS (1) | IS6286A (es) |
| MA (1) | MA26822A1 (es) |
| MX (1) | MXPA02003308A (es) |
| MY (1) | MY133996A (es) |
| NO (1) | NO20021474L (es) |
| NZ (1) | NZ517177A (es) |
| OA (1) | OA12021A (es) |
| PA (1) | PA8503301A1 (es) |
| PE (1) | PE20010696A1 (es) |
| PL (1) | PL357371A1 (es) |
| SK (1) | SK4182002A3 (es) |
| TN (1) | TNSN00191A1 (es) |
| TR (1) | TR200200843T2 (es) |
| UA (1) | UA73525C2 (es) |
| WO (1) | WO2001023399A1 (es) |
| YU (1) | YU23102A (es) |
| ZA (1) | ZA200202461B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| EP1241176A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| JP2005511590A (ja) * | 2001-11-02 | 2005-04-28 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物 |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| ATE418991T1 (de) * | 2002-04-18 | 2009-01-15 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| EP1687268A1 (en) * | 2003-11-10 | 2006-08-09 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| KR20070085093A (ko) | 2004-03-24 | 2007-08-27 | 파스젠, 엘엘씨. | Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법 |
| EA011097B1 (ru) | 2004-05-07 | 2008-12-30 | Янссен Фармацевтика Н.В. | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| WO2006011130A1 (en) * | 2004-07-28 | 2006-02-02 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome |
| WO2006015830A1 (en) * | 2004-08-09 | 2006-02-16 | Universite Catholique De Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| AU2005279209B2 (en) | 2004-08-30 | 2011-03-24 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-BETA hydroxysteroid dehydrogenase inhibitors |
| ES2338441T3 (es) | 2004-08-30 | 2010-05-07 | Janssen Pharmaceutica Nv | Derivados de n-2-adamantil-2-fenoxi-acetamida como inhibidores de 11-betahidroxiesteroide-deshidrogenasa. |
| DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| JP2010504933A (ja) | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| PT2231642E (pt) | 2008-01-11 | 2014-03-12 | Novartis Ag | Pirimidinas como inibidores de quinase |
| WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
| EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| PE20170003A1 (es) | 2009-08-17 | 2017-03-15 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| IN2012DN01453A (es) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| EA201391230A1 (ru) | 2011-02-25 | 2014-01-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов trk |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| KR102200176B1 (ko) | 2012-05-08 | 2021-01-11 | 에어로믹스, 인코포레이티드 | 신규 방법 |
| RU2559776C2 (ru) * | 2012-08-20 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| MX386250B (es) | 2013-11-06 | 2025-03-18 | Aeromics Inc | Formulaciones novedosas. |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| RU2611339C2 (ru) * | 2014-02-17 | 2017-02-21 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| EP3174869B1 (en) | 2014-07-31 | 2020-08-19 | Novartis AG | Combination therapy of a met inhibitor and an egfr inhibitor |
| RU2582961C1 (ru) * | 2015-03-04 | 2016-04-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| RU2712150C1 (ru) * | 2019-08-22 | 2020-01-24 | Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" | ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62692D0 (es) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| TW336938B (en) * | 1992-05-21 | 1998-07-21 | Pfizer | Calcium channel blocking polypeptides from filistata hibernalis |
| DE69428536T2 (de) * | 1993-07-13 | 2002-06-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A3 -adenosin -rezeptor agonisten |
-
2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 CA CA002386079A patent/CA2386079A1/en not_active Abandoned
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 EP EP00958949A patent/EP1216257B1/en not_active Expired - Lifetime
- 2000-09-22 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active Expired - Fee Related
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 HK HK03101216.3A patent/HK1049011A1/zh unknown
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/en not_active Ceased
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
-
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029887A1 (es) | Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen | |
| AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| AR072471A1 (es) | BENZOXACINAS Y BENZOTIACINAS CON ACTIVIDAD INHIBIDORA DE NOS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO EN EL TRATAMIENTO DEL DOLOR. | |
| AR035695A1 (es) | Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos | |
| AR042542A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y proceso para su preparacion | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| AR062406A1 (es) | Derivados de quinazolina como inhibidores de b-raf | |
| WO2008065500A3 (en) | Heteroaryl amides as type i glycine transport inhibitors | |
| AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
| RU96109378A (ru) | Ингибиторы протеазы вич | |
| AR003005A1 (es) | Compuestos derivados de benzamida, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, el metodo de tratamientoterapeutico y/o de prevencion con dichos compuestos, y las aplicaciones de dichos compuestos como medicamentos, y para la obtencion de medicamentos. | |
| AR038172A1 (es) | Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento | |
| AR047902A1 (es) | Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR037736A1 (es) | Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r) | |
| AR042659A1 (es) | Derivados de 4-5 diariltiazoles como ligandos de cb-1 | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| AR048401A1 (es) | Inhibidores de la serina-proteasa ns3 del vhc | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR034127A1 (es) | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento | |
| AR033836A1 (es) | Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion | |
| AR079648A1 (es) | Inhibidores de la replicacion del virus de la hepatitis c | |
| AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |